Europe Heparin Market, by Product Type (Low Molecular Weight Heparin, Unfractionated Heparin, Ultra Low Molecular Weight Heparin), by End User (Hospitals, Blood and Stem Cell Bank, Others (Laboratories, Acute Care Centers)) and by Country (Germany, France, U.K., Italy, Spain, Russia, The Netherlands, Poland, Switzerland, Sweden, and Rest of Europe) -

Published In : Jul 2023

Code : CMI3960

Pages :199

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Europe Heparin Market– Driver

Investment by key players owing the growth of market

To expand markets internationally, Europe companies are focused on investments to expand its product portfolio. For instance, On May 4, 2023, Vall Companys, agri-food group and the Bioiberica,a spain based pharmaceutical comapny have presented Biovall Heparin Science, a joint business project that will enable the production of crude heparin extracted from porcine intestinal mucosa. The project, which has been approved by the local government, is notable for being the union of two corporations in its respective sectors. Maximum traceability from the mucosa to heparin and the utmost product safety and quality.

Europe Heparin Market: Restraint

Risk of occurrence of diseases due to heparin

According to EuropPCR, based in Paris, on September 1, 2022, explained crude models showed that pretreatment with unfractionated heparin was associated with a lower risk of coronary occlusion on angiography, 30-day mortality, and major in-hospital bleeding compared with no pretreatment. Regardless of the number of covariates included in the model, the derived multivariate Poisson regression showed consistent results for coronary occlusion in angiography. However, adjusted risk estimates for in-hospital major bleeding were not significant.

To counterbalance this restraint, a robust protocol should be introduce to develop pure form of hepain drug.